| Cas No.: | 1334493-07-0 |
| Chemical Name: | 4-(N-(4-Cyclohexylbenzyl)-2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)acetamido)-2-hydroxybenzoic acid |
| Synonyms: | BP-1-102;BP 1-102;4-(N-(4-cyclohexylbenzyl)-2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)acetamido)-2-hydroxybenzoic acid;4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid;BCP24676;BDBM50353432;s7769;AK474605;4-(N-(4-cyclohexylbenzyl)-2-((2,3,4,5 |
| SMILES: | S(C1C(=C(C(=C(C=1F)F)F)F)F)(N(C([H])([H])[H])C([H])([H])C(N(C1C([H])=C([H])C(C(=O)O[H])=C(C=1[H])O[H])C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])=O)(=O)=O |
| Formula: | C29H27F5N2O6S |
| M.Wt: | 626.5915 |
| Purity: | >99% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Publication: | Improving lipid nanoparticles delivery efficiency of macrophage cells by using immunomodulatory small molecules-Lirong Yi PhD , Ziyan Zhang MSc-Nanomedicine: Nanotechnology, Biology and Medicine Volume 64, February 2025, 102809 |
| Description: | BP-1-102 is a potent, orally bioavailable and selective STAT3 inhibitor.BP-1-102 could enhance the transfection efficiency to 2-fold to 5-fold of Lipofectamine 3000 and LNP, all of which are currently approved for clinical use in the treatment of the most common malignant tumors. |
| In Vivo: | Mice therapeutically given BP-1-102, an orally bioavailable compound targeting STAT3/NF-kB activation and cross-talk, exhibit reduced colon tumorigenesis and diminished expression of STAT3/NF-kB-activating cytokines in the neoplastic areas[2]. BP-1-102 is orally bioavailable and that the agent accumulates in tumor tissues at levels sufficient to inhibit aberrantly active Stat3 functions and inhibit tumor growth[1]. |
| In Vitro: | BP-1-102 binds Stat3 with an affinity KD of 504 nM. BP-1-102 inhibits Stat3 DNA-binding activity in vitro, with an IC50 value of 6.8±0.8 μM. It blocks Stat3-phospho-tyrosine peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8[1]. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|